Cancer Vaccines in the Immunotherapy Era: Promise and Potential

Therapeutic vaccines are a promising alternative for active immunotherapy for different types of cancers. Therapeutic cancer vaccines aim to prevent immune system responses that are not targeted at the tumors only, but also boost the anti-tumor immunity and promote regression or eradication of the m...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2023-11, Vol.11 (12), p.1783
Main Authors: Verma, Chaitenya, Pawar, Vishakha Anand, Srivastava, Shivani, Tyagi, Anuradha, Kaushik, Gaurav, Shukla, Surendra Kumar, Kumar, Vinay
Format: Article
Language:English
Subjects:
Antigens
Automobile safety
Cancer
Cancer therapies
cancer vaccine
Cancer vaccines
Care and treatment
Cervical cancer
Dosage and administration
FDA approval
Human papillomavirus
immune checkpoint
Immune response
immune suppression
Immune system
Immunology
Immunotherapy
Malignancy
Methods
mRNA vaccines
Mutation
Patients
Physiological aspects
R&D
Research & development
Review
RNA polymerase
Sarcoma
Stem cells
Testing
tumor cell
tumor microenvironment
Tumors
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Therapeutic vaccines are a promising alternative for active immunotherapy for different types of cancers. Therapeutic cancer vaccines aim to prevent immune system responses that are not targeted at the tumors only, but also boost the anti-tumor immunity and promote regression or eradication of the malignancy without, or with minimal, adverse events. Clinical trial data have pushed the development of cancer vaccines forward, and the US Food and Drug Administration authorized the first therapeutic cancer vaccine. In the present review, we discuss the various types of cancer vaccines and different approaches for the development of therapeutic cancer vaccines, along with the current state of knowledge and future prospects. We also discuss how tumor-induced immune suppression limits the effectiveness of therapeutic vaccinations, and strategies to overcome this barrier to design efficacious, long-lasting anti-tumor immune responses in the generation of vaccines.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines11121783